Method of treating Rett syndrome by oral administration of acetate which is provided as composition comprising magnesium acetate, calcium acetate or ethylacetate
US9968580B2 · kind B2 · utility
0Cited by
1References
15Claims
0Family size
Inventor
Key dates
| Filing date | Aug 30, 2016 |
| Grant date | May 15, 2018 |
| Priority date | — |
| Expiry date | Aug 30, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/4858
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Genetic and epigenetic diseases and disorders are treated with FDA approved dietary compositions in the form of dietary supplements and nutraceuticals. The diseases and disorders to be treated include Rett syndrome, trinucleotide repeat diseases such as Fragile X syndrome, memory impairment, chronic inflammation, pre-cancerous conditions which involve cancer stem cells, and post-cancerous conditions which involve cancer stem cells which have survived in spite of cancer treatment. Treatment options include prophylactic treatment which is initiated prior to the development of the symptoms of the disease or disorder.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.